Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
See Latest ArticlesE-selectin, interleukin 18, serum amyloid A, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy
Journal of Rheumatology, 07/02/09
Visvanathan S et al. – Study demonstrates that treatment with golimumab (human monoclonal antibody to TNF-α) + methotrexate (MTX) therapy in patients with active rheumatoid arthritis (RA) significantly decreased several inflammatory biomarkers. Decreases in serum levels of serum amyloid A (SAA), E-selectin, and MMP-9 at wk 4 may be useful in predicting clinical response at wk 16.
Methods- Main objectives of this study were to:
- Assess the effect of golimumab + MTX on selected inflammatory biomarkers and
- Determine if these effects predict clinical response in RA
- Sera from adults with active RA despite MTX therapy, who received:
- Subcutaneous injections of placebo + MTX (n=34) or
- Golimumab 50 or 100 mg every 2 or 4 wks + MTX (n=137)
- were analyzed for levels of CRP, SAA, IL-18, E-selectin, MMP-9 and TIMP-1
- Golimumab + MTX treatment decreased serum CRP, SAA, IL-18, E-selectin, TIMP-1, and MMP-9 levels vs MTX
- This difference was noted first at wk 4; decreases were sustained through wk 16
- Larger magnitudes of decrease in all biomarkers were observed for clinical responders vs nonresponders
- Reductions in levels of SAA, E-selectin, MMP-9 at wk 4 correlated with improvement in swollen joint count (SJC) at wk 16
- Same was true for reductions in E-selectin with improvement in tender joint count at wk 16
- After accounting for the biomarkers, however, treatment group was no longer significant for SJC
Related Articles
Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia
Journal of Clinical Oncology, 11/09/09
Relevance Score: 71%
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: A randomised phase 2 trial
The Lancet, 11/05/09
Relevance Score: 69%
Effect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia
Cancer, 10/26/09
Relevance Score: 68%
Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor [alpha] therapies: Does the risk change with the time since start of treatment?
Arthritis & Rheumatism, 11/05/09
Relevance Score: 67%
Clinical potency of methotrexate, aminopterin, talotrexin and pemetrexed in childhood leukemias
Cancer Chemotherapy and Pharmacology, 10/05/09
Relevance Score: 66%
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Serum blc/cxcl13 concentrations and renal expression of cxcl13/cxcr5 in patients with systemic lupus erythematosus and lupus nephritis
Journal of Rheumatology, 12/07/09
Increased mRNA expression of collagen V gene in pulmonary fibrosis of systemic sclerosis
European Journal of Clinical Investigation, 12/04/09
The immunoregulatory role of vitamins A, D and E in patients with primary Sjogren's syndrome
Rheumatology, 12/01/09
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
MLN3897 plus methotrexate in patients with rheumatoid arthritis: Safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study
Arthritis & Rheumatism, 12/07/09
Interferon-[alpha] mediates suppression of C-reactive protein: Explanation for muted C-reactive protein response in lupus flares?
Arthritis & Rheumatism, 12/07/09
Long-term experience with etanercept in psoriatic arthritis patients: A 3-year observational study
Journal of Dermatological Treatment , 12/07/09
Today in Rheumatoid Arthritis...keeping you current
Receive free subspecialty "5-minute updates" via email
Bone marrow edema is the most specific finding for rheumatoid arthritis (RA) on noncontrast magnetic resonance imaging of the hands and wrists: A comparison of patients with RA and healthy controls
Journal of Rheumatology, 12/07/09
MLN3897 plus methotrexate in patients with rheumatoid arthritis: Safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study
Arthritis & Rheumatism, 12/07/09
Associations between the American College of Rheumatology pediatric response measures and the continuous measures of disease activity used in adult rheumatoid arthritis: A secondary analysis of clinical trial data from children with Polyarticular-Course Juvenile Idiopathic Arthritis
Arthritis & Rheumatism, 12/07/09
Sponsor
Article Search
Sponsor